ConMed has been focused on protecting inventions in European Patent Office(EPO) with 21 publications in Q3 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 23% filings and 18% grants. The European Patent Office(EPO), United States(US), South Korea(KR), and Australia(AU) patent Office are among the top ten patent offices where ConMed is filings its patents. Among the top granted patent authorities, ConMed has 23% of its grants in Canada(CA), 21% in South Korea(KR), and 18% in European Patent Office(EPO).
Johnson & Johnson could be the strongest competitor for ConMed
In terms of grant share, ConMed stands in second position among its competitors. Johnson & Johnson and Arthrex secured the top positions according to recent patent publication data.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Patents related to climate change and emissions reduction lead ConMed’s portfolio
ConMed has the highest number of patents in climate change followed by, emissions reduction and healthtech. For climate change, nearly 25% of patents were filed and 0% of patents were granted in Q3 2023.
Orthopedic devices related patents lead ConMed portfolio followed by general surgery devices, and anesthesia and respiratory devices
ConMed has highest number of patents in orthopedic devices followed by general surgery devices, anesthesia and respiratory devices, automobile lighting systems and advanced batteries. For orthopedic devices, nearly 48% of patents were filed and 42% of patents were granted in Q3 2023.
For comprehensive analysis of ConMed’s filings and grants, buy the databook here.
